Table 2 Association between PSCA staining and prostate cancer phenotype
Evaluable | PSCA staining (%) | |||||
|---|---|---|---|---|---|---|
Parameter | (N) | Negative | Weak | Moderate | Strong | P |
Total | 9642 | 46.3 | 22.4 | 24.5 | 6.8 | |
Tumor stage | ||||||
pT2 | 6003 | 41.5 | 23.6 | 26.9 | 8.0 | < 0.0001 |
pT3a | 2269 | 51.1 | 20.9 | 22.5 | 5.5 | |
pT3b-pT4 | 1326 | 59.7 | 19.5 | 17.0 | 3.8 | |
Gleason grade | ||||||
≤3 + 3 | 1713 | 47.0 | 23.0 | 22.8 | 7.2 | < 0.0001 |
3 + 4 | 5275 | 43.4 | 22.8 | 26.5 | 7.4 | |
3 + 4 Tertiary 5 | 441 | 46.3 | 23.6 | 23.8 | 6.3 | |
4 + 3 | 977 | 50.2 | 21.2 | 21.8 | 6.9 | |
4 + 3 Tertiary 5 | 666 | 48.6 | 22.8 | 23.7 | 4.8 | |
≥4 + 4 | 562 | 61.6 | 17.4 | 17.8 | 3.2 | |
Lymph node metastasis | ||||||
N0 | 5873 | 46.0 | 22.4 | 24.4 | 7.2 | < 0.0001 |
N+ | 674 | 59.9 | 19.1 | 17.7 | 3.3 | |
Preoperative PSA level (ng/ml) | ||||||
< 4 | 1099 | 48.6 | 19.7 | 25.3 | 6.4 | 0.0118 |
4–10 | 5715 | 44.9 | 23.4 | 24.7 | 7.0 | |
10–20 | 1995 | 46.9 | 21.8 | 24.1 | 7.3 | |
> 20 | 724 | 51.2 | 20.0 | 23.6 | 5.1 | |
Surgical margin | ||||||
Negative | 7544 | 45.1 | 22.8 | 24.8 | 7.3 | < 0.0001 |
Positive | 1882 | 51.3 | 20.8 | 22.6 | 5.3 | |